The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

India's Ministry of Health has released new guidelines to help identify respiratory viral illness symptoms. Early recognition ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV). Nirsevimab administration ...

Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting ...

Every year, millions of people worldwide are affected by a virus that often goes unnoticed -Respiratory Syncytial Virus (RSV). Despite its widespread prevalence, many people remain unaware of what RSV ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants, making maternal vaccination critical for newborn protection Vaccinating at 32 weeks of pregnancy optimizes ...

Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus (RSV) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. "Respiratory ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...